Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
O15120
UPID:
PLCB_HUMAN
Alternative names:
1-acylglycerol-3-phosphate O-acyltransferase 2; Lysophosphatidic acid acyltransferase beta
Alternative UPACC:
O15120; O00516; O15106; Q5VUD3; Q5VUD4; Q9BSV7; Q9BWR7
Background:
The 1-acyl-sn-glycerol-3-phosphate acyltransferase beta, also known as 1-acylglycerol-3-phosphate O-acyltransferase 2 and Lysophosphatidic acid acyltransferase beta, plays a crucial role in lipid metabolism. It catalyzes the conversion of lysophosphatidic acid (LPA) into phosphatidic acid (PA), a key intermediate in the biosynthesis of various lipids.
Therapeutic significance:
Congenital generalized lipodystrophy 1, a disorder marked by severe insulin resistance and lack of adipose tissue, is linked to mutations in this protein's gene. Understanding its function could lead to novel treatments for this and related metabolic conditions.